“Could Depression Be Caused By An Infection?” I would say Inflammation…

More accurately, could depression be caused by inflammation? People with mental illnesses often experience autoimmune illnesses, meaning their immune systems are over reactive, so much so that they are reacting against their own bodies. I am a case in point, I have food “allergies”, where my immune system reacts to certain foods and then epitopes that look similar to it in my joints and I suffer from joint pain, especially if I eat dairy. Also my thyroid has been knocked out by my own immune system. I have antibodies (autoantibodies) against my own thyroid in my blood, this is called Hashimoto’s thyroiditis. Normally TSH (thyroid stimulating hormone) levels are 0.5 – 4 mIU/L, when I found out that my thyroid had stopped working, my TSH level was 102! Which meant that my pituitary gland kept making TSH to try to make my thyroid work, but unfortunately my thyroid had been disabled by my own immune cells and couldn’t “wake up”! I also have eczema, an autoimmune disease of the skin, thank goodness it’s not too severe. The composer Robert Schumann’s sister suffered from severe eczema and eventually committed suicide. I wonder how much depression played a part in this? I suspect it played a big part.

Another case in point, my mother, who suffered from drug resistant depression with bipolar II, also suffered from rheumatoid arthritis and lupus, both autoimmune illnesses. Same gene pool you say, well look at this article called “Autoimmune Diseases and Severe Infections as Risk Factors for Mood DisordersA Nationwide Study” from: http://archpsyc.jamanetwork.com/article.aspx?articleid=1696348 In this study, Danish researches “found a strong correlation between infection, autoimmune disorders, and mood disorders, strengthening the hypothesis that depression is directly linked to inflammation.” Also from the same study “In a population-based study, Eaton et al found a 70% increased risk of developing bipolar disorder (n = 9920) within 4 years of an autoimmune disease diagnosis and a 20% increased risk in the time span from 5 years onward after the diagnosis compared with the background population.” This pretty significant. Why aren’t drug companies investigating this? A drug that is used widely called Lamictal, a treatment for bipolar II, actually increases the activity of the immune system, making people more prone to “the deadly rash” aka Stevens-Johnson syndrome, an immunologically induced rash which can be deadly if not treated. When I was on it (disastrously, I might add) between 2002 -2008, that was when my joint ache, tendonitis, bursitis problems started. And my mood became worse and worse until I had myself hospitalized at Columbia Presbyterian, and Lithium saved the day!

Moods, autoimmunity and inflammation, definitely related, I actually wrote a long discourse on this very thing in late 2008 in a manic phase, if I can find it and if it makes sense, I will post it here, In the meantime, pharmaceutical companies seriously need to start doing some research on autoimmunity, inflammation and mood disorders. Perhaps an email to my new friends at Astra Zeneca is in order 🙂

_________________________________________________________________________________

http://www.npr.org/sections/health-shots/2015/10/25/451169292/could-depression-be-caused-by-an-infection?utm_source=facebook.com&utm_medium=social&utm_campaign=npr&utm_term=nprnews&utm_content=2050

Could Depression Be Caused By An Infection?

OCTOBER 25, 2015 6:01 AM ET
Katherine Streeter for NPR

Katherine Streeter for NPR

Sometime around 1907, well before the modern randomized clinical trial was routine, American psychiatrist Henry Cotton began removing decaying teeth from his patients in hopes of curing their mental disorders. If that didn’t work he moved on to more invasive excisions: tonsils, testicles, ovaries and, in some cases, colons.

Cotton was the newly appointed director of the New Jersey State Hospital for the Insane and was acting on a theory proposed by influential Johns Hopkins psychiatrist Adolph Meyer, under whom Cotton had studied, that psychiatric illness is the result of chronic infection. Meyer’s idea was based on observations that patients with high fevers sometimes experience delusions and hallucinations.

Cotton ran with the idea, scalpel in hand.

Pulled Teeth Eliminate Hallucinations

This 1920 newspaper clipping from The Washington Herald highlights Dr. Henry Cotton’s practice of removing infected teeth to treat mental health problems.

A 1920 newspaper clipping from The Washington Herald.

Library of Congress

In 1921 he published a well-received book on the theory called The Defective Delinquent and Insane: the Relation of Focal Infections to Their Causation, Treatment and Prevention. A few years later The New York Times wrote, “eminent physicians and surgeons testified that the New Jersey State Hospital for the Insane was the most progressive institution in the world for the care of the insane, and that the newer method of treating the insane by the removal of focal infection placed the institution in a unique position with respect to hospitals for the mentally ill.” Eventually Cotton opened a hugely successful private practice, catering to the infected molars of Trenton, N.J., high society.

Following his death in 1933, interest in Cotton’s cures waned. His mortality rates hovered at a troubling 45 percent, and in all likelihood his treatments didn’t work. But though his rogue surgeries were dreadfully misguided and disfiguring, a growing body of research suggests that there might be something to his belief that infection – and with it inflammation – is involved in some forms of mental illness.

Symptoms Of Mental And Physical Illness Can Overlap

Late last year Turhan Canli, an associate professor of psychology and radiology at Stony Brook University, published a paper in the journal Biology of Mood and Anxiety Disorders asserting that depression should be thought of as an infectious disease. “Depressed patients act physically sick,” says Canli. “They’re tired, they lose their appetite, they don’t want to get out of bed.” He notes that while Western medicine practitioners tend to focus on the psychological symptoms of depression, in many non-Western cultures patients who would qualify for a depression diagnosis report primarily physical symptoms, in part because of the stigmatization of mental illness.

“The idea that depression is caused simply by changes in serotonin is not panning out. We need to think about other possible causes and treatments for psychiatric disorders,” says Canli.

His assertion that depression results from infection might seem far-fetched, or at least premature, but there are some data to bolster his claim.

Harkening back to Adolph Meyer’s early 20th century theory, Canli notes how certain infections of the brain – perhaps most notably Toxoplasma gondii — can result in emotional disturbances that mimic psychiatric conditions. He also notes that numerous pathogens have been associated with mental illnesses, including Borna disease virus, Epstein-Barr and certain strains of herpes, including varicella zoster, the virus that causes chickenpox and shingles.

Toxoplasma gondii, a parasitic protozoan, afflicts cats and other mammals. Acute toxoplasmosis produces flu-like symptoms and has been linked to behavioral changes in humans.

Toxoplasma gondii, a parasitic protozoan, afflicts cats and other mammals. Acute toxoplasmosis produces flu-like symptoms and has been linked to behavioral changes in humans.

Eye of Science/Science Source

A Danish study published in JAMA Psychiatry in 2013 looked at the medical records of over three million people and found that any history of hospitalization for infection was associated with a 62 percent increased risk of later developing a mood disorder, including depression and bipolar disorder.

Canli believes that pathogens acting directly on the brain may result in psychiatric symptoms; but also that autoimmune activity — or the body’s immune system attacking itself — triggered by infection may also contribute. The Danish study also reported that a past history of an autoimmune disorder increases the risk of a future mood disorder by 45 percent.

Antibodies Provide A Clue

The idea there could be a relationship between the immune system and brain disease isn’t new. Autoantibodies were reported in schizophrenia patients in the 1930s. Subsequent work has detected antibodies to various neurotransmitter receptors in the brains of psychiatric patients, while a number of brain disorders, including multiple sclerosis, are known to involve abnormal immune system activity. Researchers at the University of Virginia recently identified a previously undiscovered network of vessels directly connecting the brain with the immune system; the authors concluded that an interplay between the two could significantly contribute to certain neurologic and psychiatric conditions.

Both infection and autoimmune activity result in inflammation, our body’s response to harmful stimuli, which in part involves a surge in immune system activity. And it’sthought by many in the psychiatric research community that inflammation is somehow involved in depression and perhaps other mental illnesses.

Multiple studies have linked depression with elevated markers of inflammation, including two analyses from 2010 and 2012 that collectively reviewed data from 53 studies, as well as several post-mortem studies. A large body of related research confirms that autoimmune and inflammatory activity in the brain is linked with psychiatric symptoms.

Still, for the most part the research so far finds associations but doesn’t prove cause and effect between inflammation and mental health issues. The apparent links could be a matter of chance or there might be some another factor that hasn’t been identified.

Dr. Roger McIntyre, a professor of psychiatry and pharmacology at the University of Toronto, tells Shots that he believes an upset in the “immune-inflammatory system” is at the core of mental illness and that psychiatric disorders might be an unfortunate cost of our powerful immune defenses. “Throughout evolution our enemy up until vaccines and antibiotics were developed was infection,” he says, “Our immune system evolved to fight infections so we could survive and pass our genes to the next generation. However our immune-inflammatory system doesn’t distinguish between what’s provoking it.” McIntyre explains how stressors of any kind – physical or sexual abuse, sleep deprivation, grief – can activate our immune alarms. “For reasons other than fighting infection our immune-inflammatory response can stay activated for weeks, months or years and result in collateral damage,” he says.

Unlike Canli, McIntyre implicates inflammation in general, not exclusively inflammation caused by infection or direct effects of infection itself, as a major contributor to mental maladies. “It’s unlikely that most people with a mental illness have it as a result of infection,” he says, “But it would be reasonable to hypothesize that a subpopulation of people with depression or bipolar disorder or schizophrenia ended up that way because an infection activated their immune-inflammatory system.” McIntyre says that infection, particularly in the womb, could work in concert with genetics, psychosocial factors and our diet and microbiome to influence immune and inflammatory activity and, in turn, our risk of psychiatric disease.

Trying Drugs Against Inflammation For Mental Illness

The idea that inflammation – whether stirred up by infection or other factors — contributes to or causes mental illness comes with caveats, at least in terms of potential treatments. Trials testing anti-inflammatory drugs have been overall mixed or underwhelming.

A recent meta-analysis reported that supplementing SSRIs like Prozac with regular low-dose aspirin use is associated with a reduced risk of depression and ibuprofen supplementation is linked with lower chances of obtaining psychiatric care. However concomitant treatment with SSRIs and diclofenac or celecoxib – two other anti-inflammatories often used to treat arthritis – was associated with increased risk of needing hospital care due to psychiatric symptoms.

A 2013 study explored the antidepressant potential of Remicade, an drug used in rheumatoid arthritis. Overall, three infusions of the medication were found to be no more effective than a placebo, but patients whose blood had higher levels of an inflammatory marker called C-reactive protein did experience modest benefit.

“The truth of the matter is that there is probably a subset of people who get depressed in response to inflammation,” says lead author Dr. Charles Raison, a psychiatry professor at the University of Arizona. “Maybe their bodies generate more inflammation, or maybe they’re more sensitive to it.”

How infection and other causes of inflammation and overly-aggressive immune activity may contribute to depression and other mental illnesses – and whether or not it’s actually depression driving the inflammation — is still being investigated, and likely will be for some time. But plenty of leading psychiatrists agree that the search for alternative pathologic explanations and treatments for psychiatric disorders is could help jump-start the field.

“I’m not convinced that anti-inflammatory strategies are going to turn out to be the most powerful treatments around,” cautions Raison. “But I think if we really want to understand depression, we definitely have to understand how the immune system talks to the brain. I just don’t think we’ve identified immune-based or anti-inflammatory treatments yet that are going to have big effects in depression.”

But the University of Toronto’s McIntyre has a slightly brighter outlook. “Is depression due to infection, or is it due to something else?” he asks. “The answer is yes and yes. The bottom line is inflammation appears to contribute to depression, and we have interventions to address this.”

McIntyre notes that while the science of psychiatry has a long way to go, and that these interventions haven’t been proved effective, numerous approaches with minimal side effects exist that appear to be generally anti-inflammatory, including exercise, meditation and healthy sleep habits.

He also finds promise in the work of his colleague: “Like most cases in medicine, Charles Raison showed that anti-inflammatory approaches may benefit some people with depression, but not everybody. If you try on your friend’s eyeglasses, chances are they won’t help your vision very much.”

My talk in Philadelphia (video)

I was invited to give a talk about my story of bipolar d/o and my experience with medications for bipolar d/o. The invitation was extended by Healthline.com and the talk was for Astra Zeneca drug reps and ad reps. This is a video of this talk, I made it with my iPhone. The talk was given on October 22nd, 2015, in Philadelphia. My talk was really well received 🙂 There were also two other bloggers, Jon Pressman and Julie Fast, who gave talks as well. After our talks, we had a question and answer period, where the Astra Zeneca people asked us many questions about the illness and treatment and what patients needed from them. It was a singular experience, drug companies don’t usually talk to people who suffer from illnesses for which they make medications! Even more singular for them to speak to people who have a mental illness. I commend them, and really thank Healthline.com for putting this together and allowing the drug companies and we, people who suffer from bipolar d/o, to convene and discuss issues that are important to us as patients, and to voice our opinions about what drug companies need to do to ensure better health for us. We, with all our experience and insight into this terrible illness, were given the opportunity to speak to a large pharmaceutical company such as Astra Zeneca, and they listened! And we were taken seriously! Phenomenal!

I fell in love with Philadelphia, it is such a beautiful city! I’ll post pictures I took there in another post.

Off to Philadelphia

  the city of brotherly love, tomorrow, to give my talk about my experience with bipolar disorder and its sometimes horrendous medications. Wish a sister luck! 

Talk Therapy Found to Ease Schizophrenia

http://mobile.nytimes.com/2015/10/20/health/talk-therapy-found-to-ease-schizophrenia.html?smid=fb-nytscience&smtyp=cur&_r=0&referer=http://m.facebook.com

By BENEDICT CAREYOCTOBER 20, 2015

More than two million people in the United States have a diagnosis of schizophrenia, and the treatment for most of them mainly involves strong doses of antipsychotic drugs that blunt hallucinations and delusions but can come with unbearable side effects, like severe weight gain or debilitating tremors.

Now, results of a landmark government-funded study call that approach into question. The findings, from by far the most rigorous trial to date conducted in the United States, concluded that schizophrenia patients who received smaller doses of antipsychotic medication and a bigger emphasis on one-on-one talk therapy and family support made greater strides in recovery over the first two years of treatment than patients who got the usual drug-focused care.
The report, to be published on Tuesday in The American Journal of Psychiatry and funded by the National Institute of Mental Health, comes as Congress debates mental health reform and as interest in the effectiveness of treatments grows amid a debate over the possible role of mental illness in mass shootings.
Its findings have already trickled out to government agencies: On Friday, the Centers for Medicare & Medicaid Services published in its influential guidelines a strong endorsement of the combined-therapy approach. Mental health reform bills now being circulated in Congress “mention the study by name,” said Dr. Robert K. Heinssen, the director of services and intervention research at the centers, who oversaw the research.
In 2014, Congress awarded $25 million in block grants to the states to be set aside for early-intervention mental health programs. So far, 32 states have begun using those grants to fund combined-treatment services, Dr. Heinssen said.
Experts said the findings could help set a new standard of care in an area of medicine that many consider woefully inadequate: the management of so-called first episode psychosis, that first break with reality in which patients (usually people in their late teens or early 20s) become afraid and deeply suspicious. The sooner people started the combined treatment after that first episode, the better they did, the study found. The average time between the first episode and receiving medical care — for those who do get it — is currently about a year and half.
The more holistic approach that the study tested is based in part on programs in Australia, Scandinavia and elsewhere that have improved patients’ lives in those countries for decades. This study is the first test of the approach in this country — in the “real world” as researchers described it, meaning delivered through the existing infrastructure, by community mental health centers.
The drugs used to treat schizophrenia, called antipsychotics, work extremely well for some people, eliminating psychosis with few side effects; but most who take them find that their bad effects, whether weight gain, extreme drowsiness, or emotional numbing, are hard to live with. Nearly three quarters of people prescribed medications for the disorder stop taking them within a year and a half, studies find.
“As for medications, I have had every side effect out there, from chills and shakes to lockjaw and lactation,” said a participant in the trial, Maggie, 20, who asked that her last name be omitted. She did well in the trial and is now attending nursing school.
Doctors praised the study results.
“I’m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,” said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.
Dr. Mary E. Olson, an assistant professor of psychiatry at the University of Massachusetts Medical School, who has worked to promote approaches to psychosis that are less reliant on drugs, said the combined treatment had a lot in common with Open Dialogue, a Finnish program developed in the 1980s. “These are zeitgeist ideas, and I think it’s thrilling that this trial got such good results,” Dr. Olson said.
In the new study, doctors used the medications as part of a package of treatments and worked to keep the doses as low as possible — in some cases 50 percent lower — minimizing their bad effects. The sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.
The team trained staff members at the selected clinics to deliver that package, and it included three elements in addition to the medication. First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person’s symptoms. Second, education for family members to increase their understanding of the disorder. And finally, one-on-one talk therapy in which the person with the diagnosis learns tools to build social relationships, reduce substance use and help manage the symptoms, which include mood problems as well as hallucinations and delusions.
For example, some patients can learn to defuse the voices in their head — depending on the severity of the episode — by ignoring them or talking back. The team recruited 404 people with first-episode psychosis, mostly diagnosed in their late teens or 20s. About half got the combined approach and half received treatment as usual. Clinicians monitored both groups using standardized checklists that rate symptom severity and quality of life, like whether a person is working, and how well he or she is getting along with family members.
The group that started on the combined treatment scored, on average, more poorly on both measures at the beginning of the trial. Over two years, both groups showed steady improvement. But by the end, those who had been in the combined program had more symptom relief, and were functioning better as well. They had also been on drug doses that were 20 percent to 50 percent lower, Dr. Kane said.
“One way to think about it is, if you look at the people who did the best — those we caught earliest after their first episode — their improvement by the end was easily noticeable by friends and family,” Dr. Kane said. The gains for those in typical treatment were apparent to doctors, but much less obvious.
Dr. Kenneth Duckworth, medical director for the National Alliance on Mental Illness, an advocacy group, called the findings “a game-changer for the field” in the way it combines multiple, individualized therapies, suited to the stage of the psychosis.

The study, begun in 2009, almost collapsed under the weight of its ambition. The original proposal called for two parallel trials, each including hundreds of first-episode patients. But recruiting was so slow for one of the trials that it was abandoned, said Dr. Heinssen.

“It’s been a long haul,” Dr. Heinssen added, “but it’s worth noting that it usually takes about 17 years for a new discovery to make it into clinical practice; or that’s the number people throw around. But this process only took seven years.”

Ravi Shavi

https://m.youtube.com/watch?v=Lqd2Pdyc55A

https://m.youtube.com/watch?v=c4oTrNTbKcU/

My nephew’s band. He is the lead singer and song writer, guitarist and dancer. Such a little heart throb!

So happy to report 

That my nephew is home! He is, obviously in a lot of pain, but that is being managed by pain medication. He sat with a couple of friends and had dinner, which I had cooked, and watched a movie. It is truly a blessing to have him home from the hospital. My cousin is relieved though still in very watchful mode. This child of hers, he graduated at the top, I mean the very top, of his class from college. Then he decided to give his rock band a go, and they are well known in Rhode Island, as well as in the rock world. He has an amazing voice and musical ability. His band has recorded at least two albums! He is very creative, he’s made a lot of videos, been in many of my brother’s art projects. He was filming a video for another friend’s band when he fell, from three stories, breaking 11 of his ribs, two vertebrae had hairline fractures, and broke seven other bones on his left side. Oh my god! It could have been so much worse, this is no picnic, but it could have been so, so much worse. I mean if he’d hit his head! I can’t even think about it.  So, we are all very grateful that he is home. He says he may have developed acrophobia, to which I said: Smart! Acrophpbia is good. Happy to have him home, healing, reflecting on his actions and learning. Love this nephew of mine very much. Hoping he has learned some valuable lessons from this awful experience.

In Providence, RI. 

I’m here, in Providence, RI. Just got here today. Yesterday, after hearing the horrific news of my dearest cousin’s son, I immediately made reservations to come here. He fell from a structure 35 ft high, broke 10 ribs, 6 other bones and perforated a lung. He is in the ICU, he is young and is slated to make a full recovery. I am so happy about that. I came here for my cousin. We grew up together, spent every summer vacation together. Played, quarreled, made up, grew up together, like sisters. I couldn’t bear for her to live through this near catastrophe by herself, so I jumped in a plane and got here as quickly as I could. Saw my nephew in the ICU, obviously not anything I wanted to have ever seen. But he will recover. He was on top of this structure in downtown Providence, filming a video for his friends’ band when he lost his footing. Luckily, oh so luckily, his friends called 911 and he was taken to the hospital. Were they drinking? Probably. Was it an incredibly stupid thing to do? Absolutely! Is my cousin terrified? Yes. It’s not this incident, it’s worrying from now on, a mother’s anxiety about her son’s safety. I know this well, so I came to help her with all of it. And to drum it in her head that yes, bad things can happen, but there is recovery, and better times ahead. I hope my nephew has learnt a valuable lesson, to never be so careless with himself, with his own safety. When he is not in so much pain, I will gently talk to him. And I hope his parents will talk to him and make him promise to be infinitely more careful! No more death defying feats, as my brother said, it’s been defied. Now only a promise, one, I hope and pray for my cousin, his mother’s sake, that my nephew will keep.

New Pilot Study Finds the Fisher Wallace Stimulator® Effective in Treating Bipolar Depression

http://www.fisherwallace.com/pages/safety-and-efficacy-of-cranial-electrotherapy-stimulation

A pilot study conducted at Mount Sinai Beth Israel and published in the Journal of Nervous and Mental Disease shows that Bipolar II Depression (BD II) patients who received daily treatment with the Fisher Wallace Stimulator® experienced significant reduction in self-reported depression symptoms compared to patients using a placebo device. No side effects or adverse events were experienced by patients in the study.
The double-blind, placebo-controlled study investigated the safety and effectiveness of the Fisher Wallace Stimulator®, the leading brand of cranial electrotherapy stimulation device, for the treatment of Bipolar II Depression (BD II). After randomization, the active group received 2 mA of cranial electrotherapy stimulation for 20 minutes on a daily basis, five days a week for two weeks, whereas the placebo group had the placebo device turned on and off. Symptom nonremitters from both groups received an additional 2 weeks of open-label active treatment. Active treatment but not placebo treatment was associated with a significant decrease in the Beck Depression Inventory (BDI) scores from baseline to the second week maintaining significance until week 4.
Chip Fisher, President of Fisher Wallace Laboratories, said: “We are very grateful to the world-class team at Mount Sinai, led by Dr. Igor Galynker, that performed this research and statistical analysis with a level of integrity that is unimpeachable. The emergence of our device as a low-risk treatment option for bipolar depression will profoundly improve outcomes for millions of patients.”
Designed to be used at home for 20 minutes on a daily basis, the device works by gently stimulating the brain to produce serotonin and other neurotransmitters that improve mood and sleep, and there is evidence that it improves the brain’s ability to regulate the limbic system. The Fisher Wallace Stimulator® has been proven to be safe and effective in multiple published studies and causes no serious side effects.
Kelly Roman, CMO of Fisher Wallace Laboratories, said: “Today is a milestone in the evolution of wearable technology. Patients who suffer from bipolar depression can start using this device today, and psychiatrists can feel confident about it from a risk benefit perspective.”
Fisher Wallace Laboratories manufactures and markets the Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia. The Fisher Wallace Stimulator® is also approved by Health Canada for over-the-counter treatment of insomnia and chronic pain, and by the European Union for over-the-counter treatment of depression, anxiety and insomnia. To purchase or rent a device, patients may visit http://www.fisherwallace.com.
The Richard and Cynthia Zirinsky Center for Bipolar Disorder at Mount Sinai Beth Israel, formerly the Family Center for Bipolar Disorder, is one of the nation’s leading research institutions and clinics that focuses on the treatment of bipolar disorder. Director Igor Galynker, MD, PhD, is also Professor of Psychiatry and Associate Chairman for Research, Icahn School of Medicine.